Printer Friendly

Articles from M2 Pharma (September 18, 2017)

1-14 out of 14 article(s)
Title Author Type Words
Alexion Pharmaceuticals Friedman to Its Board of Directors. 374
BioCardia to Present Heart Failure Trial Design at Cardiovascular Regenerative Medicine Symposium in Houston. 320
Biohaven Partners with ADCS in Clinical Trial of Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease. Clinical report 349
Braeburn Pharmaceuticals submits NDA with priority review designation for CAM2038 with the US FDA for opioid use disorder. 298
Bristol-Myers Squibb names new director. 163
Edstrom Industries completes combination with Triple Red. 157
Former President and CEO of Incyte Joins Alexion Board of Directors. 348
Imara Study Shows Favourable Results of IMR-687 in Sickle Cell Disease. 247
James Cardia to Manage Business Development and Partnering at RXi Pharmaceuticals with Departure of Chief Business Officer Eliseev. 357
Regeneron & Sanofi partnership reports positive results for DUPIXENT in patients with moderate-to-severe atopic dermatitis. Clinical report 293
SBIR Grant to Support Advancement of Afraxis Enhanced Spine Profiling Platform. 290
TherapeuticsMD Submits Additional Endometrial Safety Information to FDA for NDA for TX-004HR. 284
TransCelerate BioPharma Adds Novartis Industry Collaboration. 254
UCB awarded US FDA approval for sNDA for BRIVIACT as monotherapy for epileptic patients 16 years and older. 324

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters